THE BIOASSAY OF LONG-ACTING THYROID STIMULATOR: A COMPARISON OF TWO METHODS

1971 ◽  
Vol 49 (3) ◽  
pp. 487-492 ◽  
Author(s):  
JANICE M. ENSOR ◽  
PAT KENDALL-TAYLOR ◽  
D. S. MUNRO ◽  
B. R. SMITH

SUMMARY The McKenzie (1958) assay method and an in-vitro assay method (Brown & Munro, 1967) for the determination of long-acting thyroid stimulator have been compared. Differences in the results were not great: the in-vitro method is simpler to perform and more precise. The sensitivity of the two methods is similar. The in-vitro method, when used with antiserum to thyroid-stimulating hormone in the medium, provided a satisfactory and simple means for the assay of long-acting thyroid stimulator in the serum of thyrotoxic patients.

2020 ◽  
Vol 386 ◽  
pp. 114831 ◽  
Author(s):  
Darja Gramec Skledar ◽  
Václav Tvrdý ◽  
Maša Kenda ◽  
Anamarija Zega ◽  
Milan Pour ◽  
...  

1955 ◽  
Vol 33 (2) ◽  
pp. 209-216 ◽  
Author(s):  
K. W. McKerns ◽  
E. Nordstrand

The ability of corticotrophin to increase the corticoid output of rat adrenals in an isolated gland system has been developed as a useful assay method for the measurement of corticotrophin potency. The extra corticoids produced by stimulation are measured in terms of cortisone. Log dose response curves are presented for corticotrophin levels from 0.002 to 0.135 I.U./100 mgm. adrenals. A four point assay design, the precision of corticoid measurements, and the characteristics of the log dose response curves for a number of types of corticotrophin are given. With four measurements of each dose level the average lambda s/b for 20 assays was 0.209 ± 0.085 (S.D.).


1955 ◽  
Vol 33 (1) ◽  
pp. 209-216
Author(s):  
K. W. McKerns ◽  
E. Nordstrand

The ability of corticotrophin to increase the corticoid output of rat adrenals in an isolated gland system has been developed as a useful assay method for the measurement of corticotrophin potency. The extra corticoids produced by stimulation are measured in terms of cortisone. Log dose response curves are presented for corticotrophin levels from 0.002 to 0.135 I.U./100 mgm. adrenals. A four point assay design, the precision of corticoid measurements, and the characteristics of the log dose response curves for a number of types of corticotrophin are given. With four measurements of each dose level the average lambda s/b for 20 assays was 0.209 ± 0.085 (S.D.).


1970 ◽  
Vol 47 (3) ◽  
pp. 333-338 ◽  
Author(s):  
PAT KENDALL-TAYLOR ◽  
D. S. MUNRO

SUMMARY The effects of dibutyryl cyclic 3′,5′-adenosine monophosphate (DBc-AMP) on the mouse thyroid gland have been investigated in the in-vitro assay of Brown & Munro (1967). The distribution of 131I-labelled compounds in the glands and the supporting medium have been analysed by thin-layer chromatography and the changes induced by cyclic 3′,5′-adenosine monophosphate (c-AMP), DBc-AMP or thyroid-stimulating hormone (TSH) compared. The release of 131I was increased when the glands were incubated with DBc-AMP, c-AMP or TSH. The potency of DBc-AMP was approximately 50 times that of c-AMP on a basis of molarity. Like TSH, DBc-AMP increased the proportion of iodothyronines in the system as a whole, whereas c-AMP had little effect. The possible explanations for this are discussed.


2014 ◽  
Vol 26 (8) ◽  
pp. 1142 ◽  
Author(s):  
Sunyoung Jung ◽  
Youngjin Park ◽  
YoungHoon Kim ◽  
Yu Yon Kim ◽  
Hyun-Ji Choi ◽  
...  

Although several long-acting follicle-stimulating hormone (FSH) therapies have been developed to enhance the ovarian response, a disadvantage of FSH therapy is its relatively short half-life, which requires women to receive one to two injections per day for almost 2 weeks. In the present study, we developed a novel FSH analogue by conjugating recombinant human FSH (rhFSH) and the constant region of the human immunoglobulin G4 fragment via non-peptidyl linkers. The efficacy of the FSH analogue was evaluated in vitro by cAMP level assessments, pharmacokinetic studies and a determination of ovarian weight and by comparing these findings with the results from other FSH analogues. In addition, the total number of antral and Graafian follicles was determined after 7 days of treatment with control, 6 µg kg–1 follitropin β, 6, 12 or 42 µg kg–1 corifollitropin α or 3, 6 or 12 µg kg–1 long acting protein/peptide discovery-follicle-stimulating hormone (LAPS-FSH). As a result, the animals treated with 12 µg kg–1 LAPS-FSH produced additional and larger healthy follicles. These data demonstrate that LAPS-FSH promotes growth and inhibits atresia of the ovarian follicle compared with other available drugs, suggesting that our new drug enhances the efficacy and duration of treatment. It is expected that our new FSH analogue will result in a higher chance of pregnancy in patients who are unresponsive to other drugs.


2014 ◽  
Vol 153 ◽  
pp. 130-133 ◽  
Author(s):  
Gema Flores ◽  
Fernando De la Peña Moreno ◽  
Gracia Patricia Blanch ◽  
Maria Luisa Ruiz del Castillo

2006 ◽  
Vol 13 (1) ◽  
pp. 19-25 ◽  
Author(s):  
Erik L. Munson ◽  
Dean T. Nardelli ◽  
K. H. Kevin Luk ◽  
Monica C. Remington ◽  
Steven M. Callister ◽  
...  

ABSTRACT Determination of the immunological mediators responsible for promoting the production of borreliacidal antibody may facilitate the development of an improved borreliosis vaccine for human and veterinary use. Previously, we developed an in vitro assay to determine if borreliacidal antibody production could be augmented by treatment with different cytokines. In this study, in vitro treatment of lymph node cells producing borreliacidal antibody with recombinant interleukin-6 (rIL-6) resulted in a fourfold enhancement of anti-OspA borreliacidal antibody. Moreover, rIL-6 enhanced Western immunoblot titers and increased the number of B lymphocytes. In contrast, treatment of anti-OspA borreliacidal antibody-producing cells with anti-IL-6 resulted in a fourfold reduction in borreliacidal activity. Treatment with anti-IL-6 also inhibited enhanced borreliacidal antibody production induced by anti-gamma interferon. These data suggest that IL-6 plays a significant role in the production of anti-OspA borreliacidal antibodies.


2004 ◽  
Vol 325 (1) ◽  
pp. 85-91 ◽  
Author(s):  
Abhai K Tripathi ◽  
Shabana I Khan ◽  
Larry A Walker ◽  
Babu L Tekwani

Sign in / Sign up

Export Citation Format

Share Document